Effect of 5-aminolevulinic acid-based photodynamic therapy via reactive oxygen species in human cholangiocarcinoma cells

Int J Nanomedicine. 2011:6:1357-63. doi: 10.2147/IJN.S21395. Epub 2011 Jun 30.

Abstract

Cancer cells have been reported to exhibit an enhanced capacity for protoporphyrin IX (PpIX) synthesis facilitated by the administration of 5-aminolevulinic acid (ALA). We investigated the effect of ALA-based photodynamic therapy (PDT) on human cholangiocarcinoma cells (HuCC-T1). Since protoporphyrin IX (PpIX), a metabolite of ALA, can produce reactive oxygen species (ROS) under irradiation and then induce phototoxicity, ALA-based PDT is a promising candidate for the treatment of cholangiocarcinoma. When various concentrations of ALA (0.05-2 mM) were used to treat HuCC-T1 cells for 6 or 24 hours, the intracellular PpIX level increased according to the ALA concentration and treatment time. Furthermore, an increased amount of PpIX in HuCC-T1 cells induced increased production of ROS by irradiation, resulting in increased phototoxicity.

Keywords: ALA-based photodynamic therapy; HuCC-T1; ROS; protoporphyrin IX.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminolevulinic Acid / pharmacology*
  • Annexin A5
  • Apoptosis / drug effects
  • Cell Line, Tumor
  • Cholangiocarcinoma / drug therapy*
  • Cholangiocarcinoma / metabolism
  • Flow Cytometry
  • Humans
  • Necrosis
  • Photochemotherapy / methods*
  • Photomicrography
  • Photosensitizing Agents / pharmacology*
  • Propidium
  • Protoporphyrins / pharmacology*
  • Reactive Oxygen Species / analysis
  • Reactive Oxygen Species / metabolism*

Substances

  • Annexin A5
  • Photosensitizing Agents
  • Protoporphyrins
  • Reactive Oxygen Species
  • Propidium
  • Aminolevulinic Acid
  • protoporphyrin IX